Antiarrhythmic potential of drugs targeting the cardiac ryanodine receptor ca2+release channel: Case study of dantrolene

K. Acsai, N. Nagy, Zoltán Márton, Kinga Oravecz, A. Varró

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Driven by the limitations of the traditional antiarrhythmic pharmacology, current antiarrhythmic research is trying to identify new avenues for the development of specific and safe antiarrhythmic drugs. One of the most promising approaches in this field is the amelioration of the abnormal events in cellular Ca2+handling originating from the dysfunction of ryanodine receptor Ca2+ release complex (RyR), which is an inevitable key factor in the pathology of myocardial dysfunction, remodeling and arrhythmogenesis. Accordingly, both in experimental and clinical situations, inhibition of abnormal activity of RyR, regardless of being the primary cause or a consequence during the pathogenesis appears to exert beneficial effect on disease outcome, including a marked antiarrhythmic defense. Considerable amount of our knowledge in this field originates from studies using dantrolene, a human drug with RyR stabilizing effect. Our review summarizes the cardiovascular pharmacology of dantrolene and the results of its use in experimental models of cardiac diseases, which emphasize a promising perspective for the possible antiarrhythmic application of RyR inhibition in the future.

Original languageEnglish
Pages (from-to)1062
Number of pages1
JournalCurrent Pharmaceutical Design
Volume21
Issue number8
Publication statusPublished - Jan 1 2015

Fingerprint

Dantrolene
Ryanodine Receptor Calcium Release Channel
Anti-Arrhythmia Agents
Drug Delivery Systems
Pharmacology
Heart Diseases
Theoretical Models
Pathology
Research
Pharmaceutical Preparations

Keywords

  • 1072
  • Arrhythmia
  • Carelease
  • Dantrolene
  • Delayed after-depolarization
  • Ryanodine-receptor

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Antiarrhythmic potential of drugs targeting the cardiac ryanodine receptor ca2+release channel : Case study of dantrolene. / Acsai, K.; Nagy, N.; Márton, Zoltán; Oravecz, Kinga; Varró, A.

In: Current Pharmaceutical Design, Vol. 21, No. 8, 01.01.2015, p. 1062.

Research output: Contribution to journalArticle

@article{975afc6b865845198c06bf85137603df,
title = "Antiarrhythmic potential of drugs targeting the cardiac ryanodine receptor ca2+release channel: Case study of dantrolene",
abstract = "Driven by the limitations of the traditional antiarrhythmic pharmacology, current antiarrhythmic research is trying to identify new avenues for the development of specific and safe antiarrhythmic drugs. One of the most promising approaches in this field is the amelioration of the abnormal events in cellular Ca2+handling originating from the dysfunction of ryanodine receptor Ca2+ release complex (RyR), which is an inevitable key factor in the pathology of myocardial dysfunction, remodeling and arrhythmogenesis. Accordingly, both in experimental and clinical situations, inhibition of abnormal activity of RyR, regardless of being the primary cause or a consequence during the pathogenesis appears to exert beneficial effect on disease outcome, including a marked antiarrhythmic defense. Considerable amount of our knowledge in this field originates from studies using dantrolene, a human drug with RyR stabilizing effect. Our review summarizes the cardiovascular pharmacology of dantrolene and the results of its use in experimental models of cardiac diseases, which emphasize a promising perspective for the possible antiarrhythmic application of RyR inhibition in the future.",
keywords = "1072, Arrhythmia, Carelease, Dantrolene, Delayed after-depolarization, Ryanodine-receptor",
author = "K. Acsai and N. Nagy and Zolt{\'a}n M{\'a}rton and Kinga Oravecz and A. Varr{\'o}",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "21",
pages = "1062",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Antiarrhythmic potential of drugs targeting the cardiac ryanodine receptor ca2+release channel

T2 - Case study of dantrolene

AU - Acsai, K.

AU - Nagy, N.

AU - Márton, Zoltán

AU - Oravecz, Kinga

AU - Varró, A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Driven by the limitations of the traditional antiarrhythmic pharmacology, current antiarrhythmic research is trying to identify new avenues for the development of specific and safe antiarrhythmic drugs. One of the most promising approaches in this field is the amelioration of the abnormal events in cellular Ca2+handling originating from the dysfunction of ryanodine receptor Ca2+ release complex (RyR), which is an inevitable key factor in the pathology of myocardial dysfunction, remodeling and arrhythmogenesis. Accordingly, both in experimental and clinical situations, inhibition of abnormal activity of RyR, regardless of being the primary cause or a consequence during the pathogenesis appears to exert beneficial effect on disease outcome, including a marked antiarrhythmic defense. Considerable amount of our knowledge in this field originates from studies using dantrolene, a human drug with RyR stabilizing effect. Our review summarizes the cardiovascular pharmacology of dantrolene and the results of its use in experimental models of cardiac diseases, which emphasize a promising perspective for the possible antiarrhythmic application of RyR inhibition in the future.

AB - Driven by the limitations of the traditional antiarrhythmic pharmacology, current antiarrhythmic research is trying to identify new avenues for the development of specific and safe antiarrhythmic drugs. One of the most promising approaches in this field is the amelioration of the abnormal events in cellular Ca2+handling originating from the dysfunction of ryanodine receptor Ca2+ release complex (RyR), which is an inevitable key factor in the pathology of myocardial dysfunction, remodeling and arrhythmogenesis. Accordingly, both in experimental and clinical situations, inhibition of abnormal activity of RyR, regardless of being the primary cause or a consequence during the pathogenesis appears to exert beneficial effect on disease outcome, including a marked antiarrhythmic defense. Considerable amount of our knowledge in this field originates from studies using dantrolene, a human drug with RyR stabilizing effect. Our review summarizes the cardiovascular pharmacology of dantrolene and the results of its use in experimental models of cardiac diseases, which emphasize a promising perspective for the possible antiarrhythmic application of RyR inhibition in the future.

KW - 1072

KW - Arrhythmia

KW - Carelease

KW - Dantrolene

KW - Delayed after-depolarization

KW - Ryanodine-receptor

UR - http://www.scopus.com/inward/record.url?scp=84925880664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925880664&partnerID=8YFLogxK

M3 - Article

C2 - 25354182

AN - SCOPUS:84925880664

VL - 21

SP - 1062

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 8

ER -